2/17
04:00 am
ocs
Oculis Appoints Katie Kazem as Chief Legal Officer
Low
Report
Oculis Appoints Katie Kazem as Chief Legal Officer
1/12
01:41 am
ocs
Oculis Holding (NasdaqGM:OCS) Valuation Check As Privosegtor Wins FDA Breakthrough Therapy Status [Yahoo! Finance]
Low
Report
Oculis Holding (NasdaqGM:OCS) Valuation Check As Privosegtor Wins FDA Breakthrough Therapy Status [Yahoo! Finance]
1/11
06:40 am
ocs
Why Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis [Yahoo! Finance]
Low
Report
Why Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis [Yahoo! Finance]
1/8
04:00 am
ocs
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
Medium
Report
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
1/6
04:23 am
ocs
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis [Yahoo! Finance]
Medium
Report
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis [Yahoo! Finance]
1/6
04:00 am
ocs
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
Medium
Report
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
12/19
10:09 am
ocs
Oculis (NASDAQ:OCS) had its price target raised by analysts at Stifel Nicolaus from $35.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Oculis (NASDAQ:OCS) had its price target raised by analysts at Stifel Nicolaus from $35.00 to $40.00. They now have a "buy" rating on the stock.
12/19
08:04 am
ocs
Oculis (NASDAQ:OCS) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $38.00 price target on the stock.
Low
Report
Oculis (NASDAQ:OCS) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $38.00 price target on the stock.
12/3
09:05 am
ocs
Oculis (NASDAQ:OCS) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $55.00 price target on the stock.
Low
Report
Oculis (NASDAQ:OCS) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $55.00 price target on the stock.